Health-related quality of life among adult patients with moderate and severe von Willebrand disease

Journal of Thrombosis and Haemostasis

Volumn 8, Issue 7, 2010, Pages 1492-1499

  De Wee, E M ^a   Mauser Bunschoten, E P ^b   Van Der Bom, J G ^c   Degenaar Dujardin, M E L ^d   Eikenboom, H C J ^c   Fijnvandraat, K ^e   De Goede Bolder, A ^f   Laros Van Gorkom, B A P ^g   Meijer, K ^h   Raat, H ^a   Leebeek, F W G ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Netherlands Hemophilia Society   (Netherlands)

^e EMMA CHILDREN S HOSPITAL   (Netherlands)

^f SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bleeding disorders; Health related quality of life; Von Willebrand disease

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; EDUCATIONAL STATUS; EMPLOYMENT; FEMALE; HEALTH STATUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCORING SYSTEM; SOCIAL INTERACTION; VON WILLEBRAND DISEASE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH STATUS; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; SEX FACTORS; VON WILLEBRAND DISEASES; YOUNG ADULT;

EID: 77955042246     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2010.03864.x     Document Type: Article

References (43)

1. Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, Meyer D, Peake I, Rodeghiero F, Srivastava A. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost 2000, 84:160-74.
2. Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand's disease. Blood 1987, 69:454-9.
3. Ruggeri ZM. Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 2001, 14:257-79.
4. Sadler JE, Budde U, Eikenboom JC, Favaloro EJ, Hill FG, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006, 4:2103-14.
5. Kessler CM. Diagnosis and treatment of von Willebrand disease: new perspectives and nuances. Haemophilia 2007, 13(Suppl. 5):3-14.
6. James AH. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 2007, 120(Suppl. 1):S17-20.
7. Kouides PA. Current understanding of von Willebrand's disease in women - some answers, more questions. Haemophilia 2006, 12(Suppl. 3):143-51.
8. Kadir RA, Chi C. Women and von Willebrand disease: controversies in diagnosis and management. Semin Thromb Hemost 2006, 32:605-15.
9. Mannucci PM. Treatment of von Willebrand's disease. N Eng J Med 2004, 351:683-94.
10. Guyatt GH, Feeny DH, Patrick DL. Measuring health-related quality of life. Ann Inter Med 1993, 118:622-9.
11. Foster PA. The reproductive health of women with von Willebrand Disease unresponsive to DDAVP: results of an international survey. On behalf of the Subcommittee on von Willebrand Factor of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995, 74:784-90.
12. Fressinaud E, Meyer D. International survey of patients with von Willebrand disease and angiodysplasia. Thromb Haemost 1993, 70:546.
13. Lak M, Peyvandi F, Mannucci PM. Clinical manifestations and complications of childbirth and replacement therapy in 385 Iranian patients with type 3 von Willebrand disease. Br J Haematol 2000, 111:1236-9.
14. Silwer J. von Willebrand's disease in Sweden. Acta Paediatr Scand 1973, 238:1-159.
15. Eikenboom JC. Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. Best Pract Res Clin Haematol 2001, 14:365-79.
16. Barr RD, Sek J, Horsman J, Furlong W, Saleh M, Pai M, Walker I. Health status and health-related quality of life associated with von Willebrand disease. Am J Hematol 2003, 73:108-14.
17. Solovieva S. Clinical severity of disease, functional disability and health-related quality of life. Three-year follow-up study of 150 Finnish patients with coagulation disorders. Haemophilia 2001, 7:53-63.
18. Tosetto A, Rodeghiero F, Castaman G, Goodeve A, Federici AB, Batlle J, Meyer D, Fressinaud E, Mazurier C, Goudemand J, Eikenboom J, Schneppenheim R, Budde U, Ingerslev J, Vorlova Z, Habart D, Holmberg L, Lethagen S, Pasi J, Hill F. A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). J Thromb Haemost 2006, 4:766-73.
19. Federici AB. Clinical diagnosis of von Willebrand disease. Haemophilia. 2004, 10(Suppl. 4):169-76.
20. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med 2001, 33:350-7.
21. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992, 30:473-83.
22. van der Zee KI, Sanderman R. Het meten van de algemene gezondheidstoestand met de RAND-36: een handleiding 1993, Groningen, The Netherlands, Noordelijk Centrum voor Gezondheidsvraagstukken
23. Ware JE, Kosinski M, Keller SD. SF-36® Physical and Mental Health Summary Scales: A User's Manual 1994, Boston, MA, The Health Institute
24. McHorney CA, Ware JE, Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 1994, 32:40-66.
25. McHorney CA, Ware JE, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993, 31:247-63.
26. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te Velde A, Verrips E. Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998, 51:1055-68.
27. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1977, New York, Acedemic Press
28. Eikenboom J, Fijnvandraat K. Behandeling van de ziekte van von Willebrand. Richtlijn: Diagnostiek en Behandeling van Hemofilie en Aanverwante Hemostasestoornissen 2009, 115-26. Leebeek FW, Mauser-Bunschoten EP. eds, Alphen aan den Rijn, Van Zuiden Communications B.V.
29. Ver Elst KM, van Vliet HD, Kappers-Klunne MC, Leebeek FW. In vitro studies, pharmacokinetic studies and clinical use of a high purity double virus inactivated FVIII/VWF concentrate (Immunate) in the treatment of von Willebrand disease. Thromb Haemost 2004, 92:67-74.
30. Remor E, Young NL, von Mackensen S, Lopatina EG. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia 2004, 10(Suppl. 4):30-4.
31. Jansen NW, Roosendaal G, Lafeber FP. Understanding haemophilic arthropathy: an exploration of current open issues. Br J Haematol 2008, 143:632-40.
32. Darby SC, Ewart DW, Giangrande PL, Spooner RJ, Rizza CR, Dusheiko GM, Lee CA, Ludlam CA, Preston FE. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet 1997, 350:1425-31.
33. Makris M, Preston FE, Triger DR, Underwood JC, Choo QL, Kuo G, Houghton M. Hepatitis C antibody and chronic liver disease in haemophilia. Lancet 1990, 335:1117-9.
34. Posthouwer D, Plug I, van der Bom JG, Fischer K, Rosendaal FR, Mauser-Bunschoten EP. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005, 90:846-50.
35. Barr RD, Saleh M, Furlong W, Horsman J, Sek J, Pai M, Walker I. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002, 71:152-60.
36. Molho P, Rolland N, Lebrun T, Dirat G, Courpied JP, Croughs T, Duprat I, Sultan Y. Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. Haemophilia 2000, 6:23-32.
37. Trippoli S, Vaiani M, Linari S, Longo G, Morfini M, Messori A. Multivariate analysis of factors influencing quality of life and utility in patients with haemophilia. Haematologica 2001, 86:722-8.
38. Miners AH, Sabin CA, Tolley KH, Jenkinson C, Kind P, Lee CA. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia 1999, 5:378-85.
39. Metjian AD, Wang C, Sood SL, Cuker A, Peterson SM, Soucie JM, Konkle BA. Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease. Haemophilia 2009, 15:918-25.
40. Berntorp E, Abshire T. The von Willebrand disease prophylaxis network: exploring a treatment concept. J Thromb Haemost 2006, 4:2511-2.
41. Rodeghiero F, Castaman G, Tosetto A, Batlle J, Baudo F, Cappelletti A, Casana P, De Bosch N, Eikenboom JC, Federici AB, Lethagen S, Linari S, Srivastava A. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J Thromb Haemost 2005, 3:2619-26.
42. Gill JC, Christopherson PA, Flood VH, Friedman KD, Montgomery RR. The Zimmerman Program Investigators. Bleeding Scores in Von Willebrand Disease (VWD) Re-Visited: Analysis of the TS Zimmerman Program for the Molecular and Clinical Biology of VWD. ASH Annual Meeting Abstracts 2008, 112:425.
43. Boren M, Ramey J. Thinking aloud: reconciling theory and practice. IEEE Trans Prof Commun 2005, 43:261-78.